FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 314 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... August 11, 2025 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 On World Cancer Day, ESMO Renews a Longstanding Commitment to Closing... February 3, 2022 Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness:... October 23, 2023 Load more HOT NEWS Talking About Sexual Health Concerns With Your Cancer Care Team: How... CEDM Reveals A Clearer Image Of Potential Breast Cancer And Reduces... FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... EMA Recommends Granting a Marketing Authorisation for Erdafitinib
